ENTASIS THERAPEUTICS HOLDINGS INC. Research and Development Expense
ENTASIS THERAPEUTICS HOLDINGS INC. reported Research and Development Expense of $10.99 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-04-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-04-27
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2022-03-31 was $10.99M, a 17.31% increase year-over-year.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2021-12-31 was $8.47M, a 13.36% decline year-over-year.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2021-09-30 was $9.28M, a 1.12% decline year-over-year.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for the quarter ending 2021-06-30 was $9.99M, a 2.47% decline year-over-year.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2021 was $37.10M, a 9.55% decline from fiscal 2020.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2020 was $41.02M, a 2.13% increase from fiscal 2019.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2019 was $40.17M, a 21.55% increase from fiscal 2018.
- ENTASIS THERAPEUTICS HOLDINGS INC. research and development expense for fiscal 2018 was $33.05M, a 28.36% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $10.99M 10-Q · filed 2022-04-27 | $19.46M derived: sum of 2 quarters · filed 2022-04-27 | $28.74M derived: sum of 3 quarters · filed 2022-04-27 | $38.73M derived: sum of 4 quarters · filed 2022-04-27 |
| 2021-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $17.75M derived: sum of 2 quarters · filed 2022-03-03 | $27.73M derived: sum of 3 quarters · filed 2022-03-03 | $37.10M 10-K · filed 2022-03-03 |
| 2021-09-30 | $9.28M 10-Q · filed 2021-11-04 | $19.27M derived: sum of 2 quarters · filed 2021-11-04 | $28.64M 10-Q · filed 2021-11-04 | $38.41M derived: sum of 4 quarters · filed 2022-04-27 |
| 2021-06-30 | $9.99M 10-Q · filed 2021-08-12 | $19.36M 10-Q · filed 2021-08-12 | $29.13M derived: sum of 3 quarters · filed 2022-04-27 | $38.52M derived: sum of 4 quarters · filed 2022-04-27 |
| 2021-03-31 | $9.37M 10-Q · filed 2022-04-27 | $19.14M derived: sum of 2 quarters · filed 2022-04-27 | $28.53M derived: sum of 3 quarters · filed 2022-04-27 | $38.77M derived: sum of 4 quarters · filed 2022-04-27 |
| 2020-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $19.16M derived: sum of 2 quarters · filed 2022-03-03 | $29.40M derived: sum of 3 quarters · filed 2022-03-03 | $41.02M 10-K · filed 2022-03-03 |
| 2020-09-30 | $9.39M 10-Q · filed 2021-11-04 | $19.63M derived: sum of 2 quarters · filed 2021-11-04 | $31.25M 10-Q · filed 2021-11-04 | $42.13M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $10.24M 10-Q · filed 2021-08-12 | $21.86M 10-Q · filed 2021-08-12 | $32.74M derived: sum of 3 quarters · filed 2021-08-12 | $40.35M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $11.62M 10-Q · filed 2021-05-05 | $22.50M derived: sum of 2 quarters · filed 2021-05-05 | $30.11M derived: sum of 3 quarters · filed 2021-05-05 | $40.79M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $10.88M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-30 | $18.49M derived: sum of 2 quarters · filed 2021-04-30 | $29.16M derived: sum of 3 quarters · filed 2021-04-30 | $40.17M 10-K/A · filed 2021-04-30 |
| 2019-09-30 | $7.61M 10-Q · filed 2020-11-05 | $18.28M derived: sum of 2 quarters · filed 2020-11-05 | $29.29M 10-Q · filed 2020-11-05 | $36.22M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $10.68M 10-Q · filed 2020-08-06 | $21.68M 10-Q · filed 2020-08-06 | $28.61M derived: sum of 3 quarters · filed 2020-08-06 | $36.70M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $11.00M 10-Q · filed 2020-05-07 | $17.93M derived: sum of 2 quarters · filed 2020-05-07 | $26.02M derived: sum of 3 quarters · filed 2020-05-07 | $35.50M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $15.02M derived: sum of 2 quarters · filed 2020-03-11 | $24.50M derived: sum of 3 quarters · filed 2020-03-11 | $33.05M 10-K · filed 2020-03-11 |
| 2018-09-30 | $8.09M 10-Q · filed 2019-11-14 | $17.57M derived: sum of 2 quarters · filed 2019-11-14 | $26.11M 10-Q · filed 2019-11-14 | $33.87M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $9.48M 10-Q · filed 2019-08-12 | $18.03M 10-Q · filed 2019-08-12 | $25.78M derived: sum of 3 quarters · filed 2019-08-12 | $32.95M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $8.55M 10-Q · filed 2019-05-14 | $16.30M derived: sum of 2 quarters · filed 2019-05-14 | $23.47M derived: sum of 3 quarters · filed 2019-05-14 | |
| 2017-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $14.92M derived: sum of 2 quarters · filed 2019-03-29 | $25.75M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $7.17M 10-Q · filed 2018-11-14 | $18.00M 10-Q · filed 2018-11-14 |